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Background: The insulin receptor substrate‐1 (IRS‐1) is the primary docking molecule for the insulin‐like growth 
factor I receptor (IGF-IR), and is required for activation of the phosphatidylinositol 3’‐kinase (PI3K) pathway. IRS‐1 
activation of the (PI3K) pathway regulates IGF‐mediated survival, enhancement of cellular motility and apoptosis. 
Therefore, we attempted to ascertain whether IRS‐1 genetic variations affect an individual’s risk for non‐small cell 
lung cancer (NSCLC).
Methods: Two‐hundred and eighteen subjects, either diagnosed with NSCLC or control subjects, were matched 
by age, gender and smoking status. Genomic DNA from each subject was amplified by PCR and analyzed according 
to the restriction fragment length polymorphism (RFLP) profile to detect the IRS‐1 G972R polymorphism.
Results: The frequencies of each polymorphic variation, in the control population, were as follows: GG=103 (94.5%) 
and GR=6 (5.5%); for the NSCLC subjects, the genotypic frequencies were as follows: GG=106 (97.2%) and GR=3 
(2.8%). We could not demonstrate statistically significant differences in the genotypic distribution between the 
NSCLC and the control subjects (p=0.499, Fisher’s Exact test). The relative risk of NSCLC, associated with the IRS‐1 
G972R polymorphic variation, was 1.028 (95% CI; 0.63∼9.90). In addition, we found no differences between 
polymorphic variants with regard to the histological subtype of NSCLC.
Conclusion: We did not observe any noteworthy differences in the frequency of the IRS‐1 G972R polymorphism 
in NSCLC patients, compared to control subjects. These results suggest suggesting that, in our study population, 
the IRS‐1 G972R polymorphism does may not appear to be associated with an increased risk of NSCLC.
Key Words: Insulin receptor substrate-1, Insulin-like growth factor, Non-small cell lung cancer
This work was supported by the Korea Science and Engineering 
Fund through the Cancer Metastasis Research Center at Yonsei 
University, Seoul, Korea.
Address for correspondence: Yoon Soo Chang, M.D.
Deparatment of Internal Medicine, 8th Floor Annex Build-
ing, Gangnam Severance Hospital, 712, Eonju-ro, Dogok- 
dong, Gangnam-gu, Seoul 135-720, Korea
Phone: 82-2-2019-3309, Fax: 82-2-3463-3882
E-mail: yschang@yuhs.ac
Received: Jun. 13, 2006
Accepted: Sep. 7, 2006
This work was published in the Journal of Lung Diseases Vol-
ume 1, Number 1, Page 22∼27.
Introduction
  Non-small cell lung cancer (NSCLC) accounts for ap-
proximately 75∼80% of all lung cancers and is the 
leading cause of cancer-related death worldwide. 
NSCLC is presumed to be caused by complex interac-
tions between genetic and environmental factors. Epide-
miologic studies suggest that, in addition to environ-
mental factors, common genetic variations that have low 
penetration but high attributable risk may play an im-
portant role in the development of NSCLC.
  Insulin-like growth factors (IGFs) are synthesized by 
almost all tissues and regulate cell proliferation, differ-
entiation, and apoptosis; all important cell processes 
that contribute to tumorigenesis1. Several studies on 
cancer risk factors have suggested that high levels of 
circulating IGF-1 are associated with an increased risk 
of solid cancers, including NSCLC2-5. The binding of 
IGF-1 to its receptor (IGF-IR) results in receptor auto-
phosphorylation and the subsequent phosphorylation of 
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Table 1. Description of the study population
NSCLC Control p-valuen (%) n (%)
Age, yr Mean±S.D. 58.4±10.52 55.8±10.79 0.077
Gender Male 86 86
Female 23 23
Smoking Current 75 62 0.181
 history Ex-smoker 14 21
Non-smoker 20 26
Shc and insulin receptor substrates (IRS)-1, -2, -3, and 
-46. Although IGF signaling is transduced intracellularly, 
via an extensive signaling network with multiple alter-
native pathways, IRS-1 is the first basic cytosolic media-
tor7-10. IRS-1 is the primary docking molecule for IGF-IR 
and is required for activation of the phosphatidylinositol 
3’-kinase (PI3K) pathway, which regulates IGF-medi-
ated survival and enhancement of cellular motility, and 
is anti-apoptotic. IRS-1 is also required for activation of 
the RAS-mitogen-activated protein kinase pathway, 
which regulates cell proliferation.
  Phosphorylation of IRS-1 at Tyr608 and Tyr628 (using 
numbering based on the rat IRS-1 amino acid sequence) 
generates the major docking sites for PI3K and activates 
multiple signaling pathways including: PI3K, mitogen‐
activated protein kinase (MAPK) and Akt11,12. On the 
other hand, IRS-1 serine/threonine phosphorylation of 
50 potential sites is thought to oppose the biologic activ-
ity that is induced by tyrosine phosphorylation13. In ad-
dition to IRS-1 phosphorylation, chronic exposure to 
IGFs, mannitol, okadaic acids, high glucose and hyper-
insulinemia decrease cellular IRS-1 levels, which, in 
turn, diminish a cell’s response to apoptotic signals11,12. 
By extension, a delicate balance between “positive” 
IRS-1 tyrosine phosphorylation and “negative” serine/ 
threonine phosphorylation, with decreased IRS-1 levels 
may regulate the function of IRS-1. Shifts in this equili-
brium could lead to pathological situations13.
  In addition to posttranslational modifications, the 
most commonly detected polymorphism in human IRS- 
1, a glycine to arginine change at codon 972 (G972R), 
is associated with an increased risk of insulin resistance 
and a variety of cancers14,15. The G972R polymorphism 
is found near the C-terminus of IRS-1 and is flanked by 
two tyrosine phosphorylation consensus sites (EY941 
MLM and DY989 MTM), known binding sites for the p85
α regulatory subunit of PI3-kinase. The G972R IRS-1 
polymorphism not only reduces substrate phosphor-
ylation, but also allows IRS-1 to act as an inhibitor of 
the insulin receptor kinase, producing a global insulin 
resistance that is associated with several types of can-
cer14,16.
  Thus, we hypothesized that the IRS-1 G972R poly-
morphic variation may affect an individual’s risk for 
NSCLC. We investigated this potential relationship, us-
ing PCR-RLFP analysis to identify the G972R poly-
morphism in our study population.
Materials and Methods
1. Study population and samples
  We used genomic DNA, isolated from 109 patients, 
who had been diagnosed with NSCLC and had under-
gone surgery between 1995 and 1998, for the manage-
ment of primary tumors at Yonsei Medical Center, 
Seoul, South Korea. The NSCLC cases included 86 male 
and 23 female patients, and the mean age was 58.4± 
10.52 years. The control subjects were matched accord-
ing to age gender and smoking status with the NSCLC 
patients. Blood samples were selected from a blood 
bank, comprising 1,038 subjects who had visited 
Yong-In Severance Hospital at Yonsei University Med-
ical College in 2003, for an annual health examination, 
conducted by the National Health Insurance Institute of 
Korea. The matched control subjects included 86 males 
and 23 females with a mean age of 55.8±10.79 years 
(Table 1). The use of these samples and our ex-
perimental protocol were reviewed and approved by 
our institutional review board.
2. PCR and restriction fragment length polymorphism 
(RFLP) analysis
  The genomic DNAs were extracted from blood sam-
ples, using a QIAamp Blood Kit (Qiagen, Hilden, Ger-
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Figure 1. Sequence of exon, translation (A) and polymorphic variants (B, C) of IRS-1. Note homozygotic (G/G) (B) and
heterozygotic (G/A) (C) variant of IRS-1. †IUB code name (R means nucleotide A and G). Numbering of the exon††
and amino acid residue††† was adapted from Gene Bank Acc. #NM_005544.
Figure 2. IRS-1 G972R polymorphic variants. The repre-
sentative data from PCR-RFLP are presented in this 
figure. Heterozygote (G/A) is shown in lane 3 and homo-
zygote (G/G) in lanes 2, 4 and 5. M: DNA size marker
(lane 1).
many), or by the standard method, using proteinase-K 
digestion, followed by phenol/chloroform extraction. 
The 243-base-pair (bp) fragment, encompassing the 
G972R polymorphic site in the IRS-1 gene, was ampli-
fied using the following specific primers: 5'-TTTGGG 
AGTGATCAG TCTGGCTAC-3' for the sense strand and 
5'-CGGGTAGGCCTGCAAATGCTA-3' for the antisense 
strand. The PCR reactions were performed in a 25-μL 
volume, containing 20 ng of genomic DNA, 2.5-μL 10 
X PCR buffer, 0.2 mM of each deoxyribonucleotide tri-
phosphate (dATP, dCTP, dGTP and dTTP), 1 mM 
MgCl2, 50 pM of each primer, and 1 unit of Ampli-Taq 
Gold DNA polymerase (Perkin-Elmer, Branchburg, NJ, 
USA). After an initial 10-min denaturation step at 95oC, 
40 cycles of PCR reactions, consisting of incubations at 
95oC for 30 sec, 60oC for 1 min, and 72oC for 1 min 
were completed. These were followed by a final 15-min 
extension step at 72oC. All PCR reactions were per-
formed in a thermal cycler (GeneAmp PCR System 9700; 
Perkin-Elmer). After confirming the successful PCR am-
plification by visualization, using 2.5% agarose gel elec-
trophoresis, each PCR product was digested for 2 hr 
with 5 units of SmaI enzyme (New England Biolabs, 
Beverly, MA, USA) at 25oC and then electrophoresed on 
a 2.5% agarose gel. When the SmaI restriction site was 
present, the 243‐bp PCR fragment was divided into 212- 
and 31-bp fragments. The allele was designated either 
G or A, depending on whether the SmaI restriction site 
was present or absent, respectively. The validity of the 
PCR-RFLP analysis was verified by direct sequencing of 
several PCR samples of each genotype from Genotech 
Co. Ltd. (Daejun, Korea), using the previously de-
scribed sense and antisense primers (Figure 1, 2).
3. Statistical analysis
  A Fisher’s exact test was employed for comparison 
of the genotypic frequencies between the NSCLC and 
the control groups (Table 2). The odds ratio (OR) and 
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Table 2. Frequency of IRS1 genotype and ORs and 95%
CIs for their association with prostate cancer in sib-
ling-based study
 Gene varinat NSCLC Control OR
 (IRS-1 G972R) n (%) n (%)  (95% CI)*
      GG 106 103 1.0 (reference)
      GR   3   6 1.028 (0.63∼9.90)†
*adjused for age, †OR and 95% CI for Arg/Arg and Gly/Arg
comgined.
Table 3. Frequency of IRS-1 genotype with regard to 
pathologic stage and subtype of NSCLC
Genotype p-value*
GG GR
pStage I 39 0 0.571
II 20 1
III 43 2
IV  4 0
Pathologic Adenocarcinoma 52 1 0.738
 subtype Squamous cell carcinoma 48 2
Other cell types  6 0
*Fisher's Exact test.95% confidence interval (CI) with regard to the IRS-1 
genotypes were calculated, using conditional logistic re-
gression analysis.
Results
1. Control subject group characteristics and IRS‐1 
G972R genotypes
  The age, gender and smoking status-matched control 
subjects included 86 males and 23 females with a mean 
age of 55.8±10.79 years (Table 1). The frequencies of 
each polymorphic variation at amino acid 972 of IRS-1 
in the control population were as follows: GG=103 
(94.5%) and GR=6 (5.5%) (Table 2). Personal medical 
histories including: diabetes, hypertension and cerebro-
vascular accidents, were not affected by the IRS-1 G972R 
genotype in the control subjects (data not shown).
2. NSCLC patient characteristics and IRS‐1 GR972R 
genotypes
  The NSCLC cases included 86 male and 23 female pa-
tients with a mean age of 58.4±10.52 years, com-
parable to the age distribution of the control population. 
The NSCLC population frequencies of each polymor-
phic variation at amino acid 972 in the IRS-1 gene were 
as follows: GG=106 (97.2%) and GR=3 (2.8%; Table 2). 
We found no apparent differences in the allelic frequen-
cies when the NSCLC patients were compared with the 
gender-, age- and smoking status-matched control sub-
jects (Fisher’s exact test).
3. IRS‐1 G972R polymorphism and the risk of NSCLC
  In order to examine whether the risk of NSCLC is re-
lated to the IRS-1 genotype, we conducted a conditional 
logistic regression analysis. Compared to the subjects 
with a GG genotype, the subjects with a GR genotype 
did not have a higher risk for NSCLC. The relative risk 
of NSCLC associated with the G972R polymorphism was 
1.028 (95% CI; 0.63∼9.90). Our study included 39 
(35.8%) patients with pathologic stage (pstage) I (IA 
and IB), 21 patients (19.3%) with pstage II (IIA and IIB), 
45 patients (41.3%) with pstage III (IIIA and IIIB) and 
4 patients (3.7%) with pstage IV. The IRS-1 G972R poly-
morphism had no appreciable influence on the tumor 
pstage at the time of initial diagnosis (Table 3). The 
NSCLC cases in our study included the following histo-
logical cancer subtypes: 53 (48.6%) adenocarcinomas, 
50 (45.9%) squamous cell carcinomas, and 6 (5.5%) cas-
es with other cell types, including undifferentiated, as 
well as large cell carcinoma. The distribution of each 
genotype did not differ with regard to the histological 
NSCLC subclassification (Table 3).
Discussion
  There were few differences in the genotypic dis-
tribution between the study populations, where 4.1% 
had the GR allele; these results conformed to Hardy- 
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Weinberg equilibrium. Other studies that evaluated the 
IRS-1 G972R polymorphism have reported a 5% rate of 
this genetic polymorphism. In our study, 5.5% of the 
control subjects had the IRS-1 G972R genetic poly-
morphism, which is in agreement with previous studies.
  IRS-1 is the major cytoplasmic substrate of the insulin 
receptor in most insulin-sensitive tissues. Some studies 
suggest that IRS-1 plays an important role in regulating 
insulin secretion in the pancreatic β cells20,21. Of the 
many IRS-1 gene polymorphisms that have been de-
scribed, the glycine-to-arginine substitution at codon 
972 (G972R) has been studied in conjunction with obe-
sity, polycystic ovary syndrome and non-insulin-de-
pendent diabetes, thus making this polymorphism a 
plausible variant that may alter cancer risk. The R allele 
has been associated with impaired insulin-associated 
signaling and insulin resistance is hypothesized to be 
associated with various cancers; therefore a slight in-
crease in the risk associated with the R allele could ac-
tually be an indirect result of the association of the R 
allele with obesity, decreased insulin sensitivity, dia-
betes, as well as altered insulin action and secretion.
  It has been suggested in the literature that insulin and 
IGFs may contribute substantially to the risk of many 
types of cancer. Polymorphisms in the genes that are 
involved in the regulation of IGFs serum levels may be 
associated with NSCLC. While many genes are involved 
in the process of regulating insulin-related factors, we 
assessed an IRS-1 polymorphism that had previously 
been shown to have functional significance in the regu-
lation of hormone levels and may, therefore, influence 
NSCLC risk.
  We observed no noteworthy difference between the 
frequencies of the IRS-1 G972R polymorphism in the 
case and the control populations. Conditional logistic 
regression analyses revealed no association between the 
polymorphism and NSCLC risk. The distribution of each 
polymorphic genotype did not differ with regard to the 
histological NSCLC subclassification. Some studies have 
reported that IRS-1 G972R genotypes resulted in a 70% 
increased risk of colon cancer15. However, the IRS-1 
G972R genotype has not been shown to be associated 
with an increased risk of NSCLC.
  In conclusion, we did not detect any noteworthy dif-
ference in the frequencies of the IRS-1 G972R poly-
morphism when comparing cases to controls, suggest-
ing that the IRS-1 G972R polymorphism may not be a 
marker for significant risk for NSCLC in our population.
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